AGL 38.30 Increased By ▲ 0.08 (0.21%)
AIRLINK 133.25 Increased By ▲ 4.28 (3.32%)
BOP 8.85 Increased By ▲ 1.00 (12.74%)
CNERGY 4.68 Increased By ▲ 0.02 (0.43%)
DCL 8.64 Increased By ▲ 0.32 (3.85%)
DFML 39.70 Increased By ▲ 0.76 (1.95%)
DGKC 85.38 Increased By ▲ 3.44 (4.2%)
FCCL 34.84 Increased By ▲ 1.42 (4.25%)
FFBL 75.55 Decreased By ▼ -0.16 (-0.21%)
FFL 12.84 Increased By ▲ 0.02 (0.16%)
HUBC 109.80 Decreased By ▼ -0.56 (-0.51%)
HUMNL 14.14 Increased By ▲ 0.13 (0.93%)
KEL 5.40 Increased By ▲ 0.25 (4.85%)
KOSM 7.76 Increased By ▲ 0.09 (1.17%)
MLCF 41.20 Increased By ▲ 1.40 (3.52%)
NBP 70.05 Decreased By ▼ -2.27 (-3.14%)
OGDC 194.25 Increased By ▲ 5.96 (3.17%)
PAEL 26.20 Increased By ▲ 0.57 (2.22%)
PIBTL 7.39 Increased By ▲ 0.02 (0.27%)
PPL 163.85 Increased By ▲ 11.18 (7.32%)
PRL 26.39 Increased By ▲ 1.00 (3.94%)
PTC 19.47 Increased By ▲ 1.77 (10%)
SEARL 84.60 Increased By ▲ 2.18 (2.64%)
TELE 8.00 Increased By ▲ 0.41 (5.4%)
TOMCL 34.00 Increased By ▲ 1.43 (4.39%)
TPLP 8.73 Increased By ▲ 0.31 (3.68%)
TREET 17.15 Increased By ▲ 0.37 (2.21%)
TRG 60.70 Increased By ▲ 4.66 (8.32%)
UNITY 29.00 Increased By ▲ 0.22 (0.76%)
WTL 1.36 Increased By ▲ 0.01 (0.74%)
BR100 10,786 Increased By 127.6 (1.2%)
BR30 32,266 Increased By 934.6 (2.98%)
KSE100 100,083 Increased By 813.5 (0.82%)
KSE30 31,193 Increased By 160.9 (0.52%)

British biotech firm Destiny Pharma is aiming to raise more than 10 million pounds ($12.9 million) of new equity to develop drugs that target antibiotic-resistant bacterial infections, or superbugs, in hospitals, it said on Friday.
Company founder Bill Love said studies had shown its XF-73 drug candidate to be effective against the superbug MRSA, without resistance emerging through 55 repeated exposures. "The drugs are differentiated from traditional antibiotics and anti-bacterial drug approaches in that their mechanism of action targets bacterial cell membranes, killing bacteria very rapidly," he said in an interview. "Due to that mechanism of action in trials and studies we've seen no emergence of bacterial resistance to excess drug action."
Scientists are racing to develop new drugs to prevent and treat life-threatening infections caused by antibiotic-resistant bacteria. Destiny Pharma's XF-73 had completed five early stage trials, he said, and the funds raised in the listing would take the drug to the cusp of phase III studies in the prevention of post-surgical Staphylococcus aureus infections during 2019.

Comments

Comments are closed.